We are international
Donate
TEXT SIZE   

ask_dr_durie_banner



Have a question? Submit it to AskDrDurie@myeloma.org!

facebook
googleplus
twitter
youtube


If you have a question to ask Dr. Durie please email us at AskDrDurie@myeloma.org. We review all questions and will do our best to have your question answered by Dr. Durie.  You can also submit your question via one of the social media channels listed above.

 

The IMF has a vast library of information that is of interest to patients, caregivers, healthcare professionals and other interested parties.  

Click here to visit out library.





#Ask Dr. Durie
previous     next      view all

07.09.14   #AskDrDurie: Can a low white blood cell count be enough to trigger a need for myeloma therapy?

In this episode of #AskDrDurie, IMF Chairman and Co-Founder Dr. Brian G.M. Durie talks about what a low white blood cell count means when it comes to myeloma.


07.02.14   #AskDrDurie: Does age make a difference in selecting myeloma treatment?

In this episode of #AskDrDurie, IMF Chairman and Co-Founder Dr. Brian G.M. Durie discusses the important factors one must consider when selecting individualized treatment for myeloma.


06.25.14   #AskDrDurie: Is MRI testing important to see if treatment is necessary for smoldering myeloma?

In this episode of #AskDrDurie, Dr. Brian Durie discusses the importance of MRI testing, specifically when it comes to patients with smoldering myeloma.


06.18.14   #AskDrDurie: Are there maintenance therapy recommendations for myeloma patients with t(4;14)?

In this episode of #AskDrDurie, IMF Chairman and Co-Founder Dr. Brian G.M. Durie addresses a question about what kind of maintenance therapy is recommended for those myeloma patients who have the t(4;14) chromosome abnormality.


06.12.14   #AskDrDurie: Are clinical trials part of the Black Swan Research Initiative(R), and if so, how can I participate?

In this episode of #AskDrDurie, Dr. Brian Durie, IMF Chairman and Co-Founder, talks about the Black Swan Research Initiative(R)'s various clinical trials and how eligible patients can get more information and potentially participate in them.


06.04.14   #AskDrDurie: How does the new flow cytometry testing for MRD compare to molecular testing?

In this episode of #AskDrDurie, Dr. Brian G.M. Durie, IMF Chairman and Co-Founder, discusses the sensitivity and accessibility of the flow cytometry method of MRD testing. 


05.22.14   #AskDrDurie: Are PET/CT scans useful for a patient with MGUS?

In this episode of #AskDrDurie, Dr. Brian G.M. Durie, IMF Chairman, explains what MGUS means and why PET/CT scans are the most effective way to exclude unsuspected lesions that may occur in patients.


05.15.14   #AskDrDurie: In light of Tom Brokaw's recent myeloma diagnosis, is better early screening required?"

In this episode of #AskDrDurie, Dr. Brian G.M. Durie, IMF Chairman, discusses the importance of early detection screenings in order to diagnose myeloma. Find out why there is a constant need for awareness and monitoring of any changes in test results.


05.08.14   #AskDrDurie: Should Patients With Similar Types of Myeloma Form Separate Support Groups?

05.01.14   #AskDrDurie: If Myeloma Is Diagnosed, Is It Okay to Start With A Holistic Type of Approach First?

previous     next      view all